AAAS Names Winship’s Dong Moon Shin, MD, as a 2016 Fellow

Dong Moon Shin, MD

Dong Moon Shin, MD, the Frances Kelly Blomeyer Distinguished Endowed Chair in Cancer Research at Winship Cancer Institute of Emory University, has been named a Fellow of the American Association for the Advancement of Science (AAAS). Dr. Shin is Professor of Hematology and Medical Oncology, Professor of Otolaryngology, and Professor of Biomedical Engineering at the Emory University School of Medicine. He is also Director of the Head and Neck Cancer Specialized Program of Research Excellence (SPORE) Program at Winship.

Election as an AAAS Fellow is an honor bestowed upon AAAS members by their peers. This year, 391 members have been awarded this honor by AAAS for their scientifically or socially distinguished efforts to advance science or its applications.

New Fellows will be presented with an official certificate and a gold and blue (representing science and engineering, respectively) rosette pin on Saturday, February 18, 2017, at the AAAS Fellows Forum during the 2017 AAAS Annual Meeting in Boston.

As part of the Section on Medical Sciences, Dr. Shin was elected as an AAAS Fellow for his distinguished contributions in the field of carcinogenesis, molecular-driven preclinical and clinical chemoprevention and therapeutics for cancers, and anticancer drug development by nanotechnology.

Dr. Shin, a Georgia Cancer Coalition Distinguished Scholar, is a graduate of Yonsei University College of Medicine in Seoul, Korea. He completed his residency at Cook County Hospital in Chicago and his fellowship at The University of Texas MD Anderson Cancer Center. ■

AAAS Names Winship’s Dong Moon Shin, MD, as a 2016 Fellow

Study Finds Daratumumab Monotherapy Prevented or Delayed Progression From Smoldering to Active Multiple Myeloma

Study Finds Genetic Changes, Elevated Leukemia Risk in Ground Zero First Responders

MRI First Strategy May Be Safe for Prostate Cancer Detection

Addition of SBRT to Systemic Therapy May Improve Outcomes in Select Patients With Locally Advanced Hepatocellular Carcinoma

Epcoritamab Monotherapy for Pretreated Relapsed or Refractory CLL